Association of Neuropsychology Students in Training (ANST)
Follow us online!
  • Home
    • About ANST
    • ANST Leadership
    • FAQ/Contact Us
  • Membership & Interest Groups
    • Joining ANST
    • ANST Interest Groups
    • Starting an Interest Group
    • ANST Highlights
  • Training & Education
    • What's Neuropsychology?
    • Professional Definitions
    • Organizations to Know
  • ANST Media
    • ANST Blog
    • ANST Listserv
    • Webinars
    • Social Media
  • Resources
    • Conferences & Events
    • Funding
    • On the Web
    • Downloadable Materials

RESEARCH ROUNDUP: Dementia with Lewy Bodies

6/2/2014

0 Comments

 
Picture

Dementia with Lewy Bodies

Dementia with Lewy Bodies (DLB) is a progressive neurodegenerative condition that is construed on a spectrum between Alzheimer's disease and Parkinson's disease. Core symptoms of LBD are gradual cognitive decline, fluctuation in alertness, visual hallucinations, and parkinsonism (motor symptoms such as rigidity, gait changes, or bradykinesia). Pathophysiology of DLB consists of the build-up of Lewy bodies, which are composed of α-synuclein protein. Treatment and management usually includes acetylcholinesterase inhibitors, such as donepezil and rivastigmine, for cognitive symptoms and occasionally levodopa for parkinsonian features.

ABSTRACT:
Dementia with Lewy Bodies
The advent of new immunostains have improved our ability to detect limbic and cortical Lewy bodies, and it is now evident that Dementa with Lewy bodies (DLB) is the second most common neurodegenerative dementia, after Alzheimer’s disease (AD). Distinguishing DLB from AD has important implications for treatment, in terms of substances that may worsen symptoms (i.e., anticholinergic and certain neuroleptic medications) and those that may improve them (i.e., cholinesterase inhibitors, carbidopa-levodopa). Neurocognitive patterns, psychiatric features, extrapyramidal signs and sleep disturbance are helpful in differentiating DLB from AD early in the disease course. Differences in the severity of cholinergic depletion as well as type and distribution of neuropathology contribute to these clinical differences, though DLB patients with a high density of co-occuring AD pathology are less clinical distinguishable from AD. [Ferman, T. J. & Boeve, B. F. (2007), Neurologic Clinic, 25 (3), 741-760]

ABSTRACT: 
Neuropsychological Characteristics of Dementia with Lewy Bodies and Parkinson’s Disease with Dementia: Differentiation, Early Detection, and Implications for “Mild Cognitive Impairment” and Biomarkers
Parkinson’s disease with dementia (PDD) and dementia with Lewy bodies (DLB) are neurodegenerative conditions sharing a disorder of α-synuclein metabolism. Temporal differences in the emergence of symptoms and clinical features warrant the continued clinical distinction between DLB and PDD. While DLB and PDD groups’ neuropsychological profiles often differ from those in Alzheimer’s disease (AD), the diagnostic sensitivity, specificity, and predictive values of these profiles remain largely unknown. PDD and DLB neuropsychological profiles share sufficient similarity to resist accurate and reliable differentiation. Although heterogeneous cognitive changes (predominantly in memory and executive function) may manifest earlier and more frequently than previously appreciated in Parkinson’s disease (PD), and executive deficits may be harbingers of dementia, the enthusiasm to uncritically extend the concept of mild cognitive impairment (MCI) to PD should be tempered. Instead, future research might strive to identify the precise neuropsychological characteristics of the prodromal stages of PD, PDD, and DLB which, in conjunction with other potential biomarkers, facilitate early and accurate diagnosis, and the definition of neuroprotective, neurorestorative, and symptomatic treatment endpoints. [Tröster, A. (2008), Neuropsychology Review, 18, 103–119]

FURTHER READING:
  • Mild cognitive impairment associated with underlying Alzheimer’s disease versus Lewy body disease [Boeve, B.F. (2012),Parkinsonism and Related Disorders, 18S1, S41–S44]
  • Amyloid PET Imaging in Lewy Body Disorders. [Donaghy P, Thomas AJ, O'Brien JT. (2013),American Journal of Geriatric Psychiatry,doi: 10.1016/j.jagp.2013.03.001. [Epub ahead of print]
  • Dementia with Lewy bodies. Review of diagnosis and pharmacologic management. [Frank C. (2003),Canadian Family Physician, 49, 1304-1311]

About the Contributor:

Surabhi Patwardhan, Ph. D. is a post-doctoral resident in clinical neuropsychology at the Arizona Psychology Training Consortium.
0 Comments



Leave a Reply.

    RSS Feed

    An RSS Feed lets you subscribe to this blog series, and you'll receive notifications whenever a new addition is posted.
    

    Archives

    July 2018
    May 2018
    April 2018
    March 2018
    January 2018
    December 2017
    November 2017
    October 2017
    September 2017
    August 2017
    May 2017
    April 2017
    March 2017
    August 2016
    June 2016
    May 2016
    April 2016
    March 2016
    February 2016
    January 2016
    December 2015
    November 2015
    October 2015
    September 2015
    August 2015
    July 2015
    June 2015
    May 2015
    April 2015
    March 2015
    January 2015
    December 2014
    November 2014
    October 2014
    September 2014
    August 2014
    July 2014
    June 2014
    May 2014
    April 2014
    March 2014
    February 2014
    January 2014
    December 2013
    November 2013
    October 2013
    September 2013


    Categories

    All
    ANST Director's Meeting
    Chapter Rep Corner
    Neurorounds
    NPsych In The Media
    Research Roundup


    Other Blogs/Podcasts

    SCN NeuroBlog

    BrainBlogger

    Neurophilosophy


    Brain Science Podcast

    Neuropod

    Neuroscientists Talk Shop

    gradPSYCH Blog

Powered by Create your own unique website with customizable templates.